Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

Developing BRAF inhibitors for patients with atypical class II and III mutations has become an exciting area of research.

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.